Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 6, 2011-07 ,pp. : 560-575

Bentham Science Publishers

Access to resources Recommend Favorite

High Expression of Proline-Rich Tyrosine Kinase2 is Associated with Poor Survival of Hepatocellular Carcinoma via Regulating Phosphatidylinositol 3-Kinase/AKT Pathway

By Cao Jie   Chen Yao   Fu Jing   Qian You-Wen   Ren Yi-Bin   Su Bo   Luo Tao   Dai Rong-Yang   Huang Liang   Yan Jian-Jun   Wu Meng-Chao   Yan Yi-Qun   Wang Hong-Yang  

Annals of Surgical Oncology, Vol. 20, Iss. 3, 2013-12 ,pp. : 312-323

Springer Publishing Company

Access to resources Recommend Favorite

Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors

By              

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 1794-1800

Spandidos Publications

Access to resources Recommend Favorite

Inhibiteurs de tyrosine kinase ciblant le VEGFR

By Loriot Y.   Massard C.   Armand J.-P.  

Oncologie, Vol. 8, Iss. 9, 2006-11 ,pp. : 815-820

Springer Publishing Company

Access to resources Recommend Favorite

Internal tandem duplication and tyrosine kinase domain mutations in FLT3 alter the response to daunorubicin in Ba/F3 cells

By    

Biomedical Reports, Vol. 4, Iss. 1, 2016-01 ,pp. : 83-86

Science Publishers

Access to resources Recommend Favorite